Biosciences' Nimotuzumab Selected for Multinational Phase III Trial by National Cancer Centre of Singapore
Singapore investigators to coordinate 700 patient trial of EGFR targeting antibody for treatment of head and neck cancer
07-Jan-2009 -
YM BioSciences Inc. announced that the National Cancer Centre of Singapore (NCCS) has selected nimotuzumab, YM's EGFR-targeting drug, for evaluation in a multinational Phase III trial of more than 700 patients with cancers of the head and neck. The NCCS stated that it selected nimotuzumab because ...
growth factors
neck cancer
phase III studies
+7